# Efficacy and Safety of Cevira® in Patients With Cervical Histologic High-grade Squamous Intraepithelial Lesions (HSIL)

> **NCT04484415** · PHASE3 · UNKNOWN · sponsor: **Asieris MediTech (Hong Kong) Co., Ltd.** · enrollment: 402 (actual)

## Conditions studied

- Cervical Intraepithelial Neoplasia Grade 2/3

## Interventions

- **COMBINATION_PRODUCT:** Cevira®
- **COMBINATION_PRODUCT:** Placebo

## Key facts

- **NCT ID:** NCT04484415
- **Lead sponsor:** Asieris MediTech (Hong Kong) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-11-10
- **Primary completion:** 2023-12
- **Final completion:** 2023-12
- **Target enrollment:** 402 (ACTUAL)
- **Last updated:** 2022-08-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04484415

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04484415, "Efficacy and Safety of Cevira® in Patients With Cervical Histologic High-grade Squamous Intraepithelial Lesions (HSIL)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04484415. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*